Compare TRTX & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRTX | YDES |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 471.4M | 476.8M |
| IPO Year | 2015 | 2024 |
| Metric | TRTX | YDES |
|---|---|---|
| Price | $6.24 | $4.25 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $9.54 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 369.9K |
| Earning Date | 10-26-2026 | 08-31-2026 |
| Dividend Yield | ★ 16.41% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.31 | N/A |
| P/E Ratio | $30.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.57 | $1.70 |
| 52 Week High | $9.37 | $18.57 |
| Indicator | TRTX | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 39.75 |
| Support Level | $5.57 | $2.33 |
| Resistance Level | $8.74 | $5.15 |
| Average True Range (ATR) | 0.21 | 1.00 |
| MACD | 0.07 | -0.29 |
| Stochastic Oscillator | 87.59 | 0.59 |
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.